(UroToday.com) The 2024 GU ASCO annual meeting featured a session on the role of immunotherapy in advanced urothelial carcinoma and a presentation by Dr. Peter O'Donnell discussing drug sequencing, ...
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle ...
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder ...
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results